Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16197464 | 1.00 | ATM (0.41) | ATMHRH3TEAD3SIGMAR1TMEM97 | |
| SCHEMBL17567266 | 0.88 | MEN1 (0.47) | SIGMAR1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL21699513 | 0.88 | MEN1 (0.47) | SIGMAR1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL16197465 | 0.87 | ALDH1A1 (0.42) | HRH3TEAD3SIGMAR1TMEM97MEN1 | |
| SCHEMBL23298099 | 0.82 | MEN1 (0.41) | ATMHRH3SIGMAR1MEN1KMT2A | |
| SCHEMBL23298100 | 0.82 | MEN1 (0.41) | ATMHRH3SIGMAR1MEN1KMT2A | |
| SCHEMBL19717823 | 0.80 | HRH3 (0.46) | HRH3TEAD3SIGMAR1TMEM97MEN1 | |
| SCHEMBL16202140 | 0.74 | KDM4E (0.58) | SIGMAR1OPRM1ALDH1A1 | |
| SCHEMBL18522832 | 0.74 | KDM4E (0.58) | SIGMAR1OPRM1ALDH1A1 | |
| SCHEMBL25190840 | 0.73 | ALDH1A1 (0.46) | ATMHRH3MEN1KMT2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11918656-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2024-03-05 | — | — | US | disclosed |
| US-20230002316-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2023-01-05 | — | — | US | disclosed |
| US-11517625-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2022-12-06 | — | — | US | disclosed |
| US-11219693-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2022-01-11 | — | — | US | disclosed |
| US-20210038738-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2021-02-11 | — | — | US | disclosed |
| US-10912841-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2021-02-09 | — | — | US | disclosed |
| US-20190269788-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2019-09-05 | — | — | US | disclosed |
| US-10314921-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2019-06-11 | — | — | US | disclosed |
| EP-3388427-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2018-10-17 | — | — | EP | disclosed |
| EP-2989086-B1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PF MEDICAMENT (FR) | 2018-08-22 | — | — | EP | disclosed |
| US-20170043032-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-02-16 | — | — | US | disclosed |
| US-20160083420-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2016-03-24 | — | — | US | disclosed |
| US-20160068566-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2016-03-10 | — | — | US | disclosed |
| EP-2989087-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | Pierre Fabre Médicament (FR) | 2016-03-02 | — | — | EP | disclosed |
| WO-2014174062-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170043032-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | KRTCAP2, DDOST, DAD1 | ATM 2759/4885HRH3 3035/4885TEAD3 3615/4885 |
| US-20160083420-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | NR1H4, AURKC, DHCR7 | ATM 2955/4885HRH3 920/4885TEAD3 3466/4885 |
| US-10912841-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DDOST, DAD1, KRTCAP2 | ATM 2733/4885HRH3 3775/4885TEAD3 3831/4885 |
| US-11517625-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DDOST, DAD1, KRTCAP2 | ATM 2733/4885HRH3 3775/4885TEAD3 3831/4885 |
| US-20160068566-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | NR1H4, HCAR3, VDR | ATM 3268/4885HRH3 381/4885TEAD3 3033/4885 |
| US-20230002316-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | NR1H4, HCAR3, VDR | ATM 3377/4885HRH3 404/4885TEAD3 3039/4885 |
| US-11219693-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DAD1, DDOST, KRTCAP2 | ATM 2877/4885HRH3 3943/4885TEAD3 3291/4885 |
| US-11918656-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DDOST, DAD1, KRTCAP2 | ATM 2733/4885HRH3 3775/4885TEAD3 3831/4885 |
| US-20190269788-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | KRTCAP2, DDOST, DAD1 | ATM 2759/4885HRH3 3035/4885TEAD3 3615/4885 |
| US-20210038738-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | DDOST, DAD1, KRTCAP2 | ATM 2759/4885HRH3 3729/4885TEAD3 3771/4885 |
| US-10314921-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | KRTCAP2, DDOST, DAD1 | ATM 2759/4885HRH3 3035/4885TEAD3 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.